|
1.
|
|
15 p, 3.0 MB |
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
/
Rejeski, Kai (Bavarian Cancer Research Center (Alemanya)) ;
Blumenberg, Viktoria (Bavarian Cancer Research Center (Alemanya)) ;
Iacoboni, Gloria (Vall d'Hebron Institut d'Oncologia) ;
López Corral, Lucia (Centro de Investigación del Cáncer-IBMCC (Espanya)) ;
Kharboutli, Soraya (University Hospital Erlangen (Alemanya)) ;
Hernani, Rafael (Hospital Clínico Universitario (Espanya)) ;
Petrera, Agnese (German Research Center for Environmental Health (Alemanya)) ;
Müller, Niklas (University Hospital (Alemanya)) ;
Hildebrand, Friederike (University Hospital (Alemanya)) ;
Frölich, Lisa (German Cancer Consortium (Alemanya)) ;
Karschnia, Philipp (University Hospital (Alemanya)) ;
Schmidt, Christian (University Hospital (Alemanya)) ;
Cordas dos Santos, David M. (German Cancer Consortium (Alemanya)) ;
Piñana, José Luis (Hospital Clínic Universitari (València)) ;
Müller, Fabian (University Hospital Erlangen (Alemanya)) ;
Martin, Ana Africa (Centro de Investigación del Cáncer-IBMCC (Espanya)) ;
Dreyling, Martin (University Hospital (Alemanya)) ;
von Bergwelt-Baildon, Michael (Bavarian Cancer Research Center (Alemanya)) ;
Barba, Pere (Vall d'Hebron Institut d'Oncologia) ;
Subklewe, Marion (Bavarian Cancer Research Center (Alemanya)) ;
Bücklein, Veit (Bavarian Cancer Research Center (Alemanya)) ;
Universitat Autònoma de Barcelona
Early fever after chimeric antigen receptor T-cell (CAR-T) therapy can reflect both an infection or cytokine release syndrome (CRS). Identifying early infections in the setting of CRS and neutropenia represents an unresolved clinical challenge. [...]
2023 -  10.1097/HS9.0000000000000858
HemaSphere, Vol. 7 (april 2023)
|
|
|
2.
|
|
7 p, 884.3 KB |
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
/
Rejeski, Kai (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Burchert, Andreas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Sesques, Pierre (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France) ;
Fransecky, Lars (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Bücklein, Veit (Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany) ;
Trenker, Corinna (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Hernani, Rafael (Hospital Clínic Universitari (València)) ;
Naumann, Ralph (Medical Department III-Hematology and Oncology, St. Marien-Krankenhaus Siegen, Siegen, Germany) ;
Schäfer, Jonas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
Blumenberg, Viktoria (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Schmidt, Christian (Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany) ;
Sohlbach, Kristina (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany) ;
von Bergwelt-Baildon, Michael (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany) ;
Bachy, Emmanuel (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Subklewe, Marion (German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany)
2022 - 10.1182/bloodadvances.2022007776
Blood advances, Vol. 6 (august 2022) , p. 4719-4725
|
|
|
3.
|
|
14 p, 6.3 MB |
CD40-activated B cells induce anti-tumor immunity in vivo
/
Wennhold, Kerstin (Uniklinik Köln (Colònia, Alemanya)) ;
Weber, Tanja M. (Cologne Interventional Immunology (CII), Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany) ;
Klein-Gonzalez, Nela (Hospital Universitari Vall d'Hebron) ;
Thelen, Martin (Uniklinik Köln (Colònia, Alemanya)) ;
Garcia-Marquez, Maria (Uniklinik Köln (Colònia, Alemanya)) ;
Chakupurakal, Geothy (Uniklinik Köln (Colònia, Alemanya)) ;
Fiedler, Anne (Uniklinik Köln (Colònia, Alemanya)) ;
Schlösser, Hans A. (Department of General, Visceral and Cancer Surgery, University Hospital of Cologne) ;
Fischer, Rieke (Department I of Internal Medicine, University Hospital of Cologne) ;
Theurich, Sebastian (Max Planck Institute for Metabolism Research Cologne) ;
Shimabukuro-Vornhagen, Alexander (Uniklinik Köln (Colònia, Alemanya)) ;
von Bergwelt-Baildon, Michael (Uniklinik Köln (Colònia, Alemanya)) ;
Vall d'Hebron Institut de Recerca (VHIR) ;
Universitat Autònoma de Barcelona
The introduction of checkpoint inhibitors represents a major advance in cancer immunotherapy. Some studies on checkpoint inhibition demonstrate that combinatorial immunotherapies with secondary drivers of anti-tumor immunity provide beneficial effects for patients that do not show a strong endogenous immune response. [...]
2016 - 10.18632/oncotarget.7720
Oncotarget, Vol. 8 (february 2016) , p. 27740-27753
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
